PL2153841T3 - Szczepionka zawierająca peptydy Amb a 1 do zastosowania w leczeniu alergii na ambrozję - Google Patents

Szczepionka zawierająca peptydy Amb a 1 do zastosowania w leczeniu alergii na ambrozję

Info

Publication number
PL2153841T3
PL2153841T3 PL09251252T PL09251252T PL2153841T3 PL 2153841 T3 PL2153841 T3 PL 2153841T3 PL 09251252 T PL09251252 T PL 09251252T PL 09251252 T PL09251252 T PL 09251252T PL 2153841 T3 PL2153841 T3 PL 2153841T3
Authority
PL
Poland
Prior art keywords
ragweed
amb
vaccine
peptides
treatment
Prior art date
Application number
PL09251252T
Other languages
English (en)
Other versions
PL2153841T5 (pl
Inventor
Mark Larche
Roderick Peter Hafner
Paul Laidler
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41090318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2153841(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0814986A external-priority patent/GB0814986D0/en
Priority claimed from GB0815218A external-priority patent/GB0815218D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of PL2153841T3 publication Critical patent/PL2153841T3/pl
Publication of PL2153841T5 publication Critical patent/PL2153841T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
PL09251252.4T 2008-08-15 2009-05-01 Szczepionka zawierająca peptydy Amb a 1 do zastosowania w leczeniu alergii na ambrozję PL2153841T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0814986A GB0814986D0 (en) 2008-08-15 2008-08-15 Peptide for il10 production
GB0815218A GB0815218D0 (en) 2008-08-20 2008-08-20 Ragweed peptides for vaccine
EP09251252.4A EP2153841B2 (en) 2008-08-15 2009-05-01 Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy

Publications (2)

Publication Number Publication Date
PL2153841T3 true PL2153841T3 (pl) 2012-05-31
PL2153841T5 PL2153841T5 (pl) 2016-09-30

Family

ID=41090318

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09251252.4T PL2153841T5 (pl) 2008-08-15 2009-05-01 Szczepionka zawierająca peptydy Amb a 1 do zastosowania w leczeniu alergii na ambrozję

Country Status (18)

Country Link
US (3) US8491910B2 (pl)
EP (3) EP2153841B2 (pl)
JP (1) JP5788319B2 (pl)
KR (1) KR20110044787A (pl)
CN (2) CN102170897B (pl)
AT (1) ATE536880T1 (pl)
AU (1) AU2009281013B2 (pl)
BR (1) BRPI0917648A2 (pl)
CA (1) CA2734379A1 (pl)
DK (1) DK2153841T4 (pl)
EA (1) EA201170336A1 (pl)
ES (1) ES2378870T5 (pl)
HR (1) HRP20120206T4 (pl)
MX (1) MX2011001619A (pl)
PL (1) PL2153841T5 (pl)
PT (1) PT2153841E (pl)
SI (1) SI2153841T2 (pl)
WO (1) WO2010018378A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958645A1 (en) * 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
EP2153841B2 (en) * 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
US8821887B2 (en) * 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
CA2786936A1 (en) * 2010-01-14 2011-07-21 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
FI20115374A0 (fi) 2011-04-18 2011-04-18 Teknologian Tutkimuskeskus Vtt Oy Uudet hypoallergeenit
EP2723373B1 (en) * 2011-06-27 2017-06-21 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
JP2015514126A (ja) * 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
NZ707615A (en) 2012-10-30 2019-01-25 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
EP2968528B1 (en) 2013-03-15 2022-02-23 Sementis Limited Immune modulation
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776761A (en) * 1989-03-17 1998-07-07 Immulogic Pharmaceutical Corporation Nucleic acids encoding allergenic proteins from ragweed
EP0463059B1 (en) 1989-03-17 1998-12-30 Immulogic Pharmaceutical Corporation Allergenic proteins from ragweed and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
FI944697L (fi) * 1992-04-09 1994-12-07 Immulogic Pharma Corp Ambrosia artemisiifolian pääallergeenien T-soluepitoopit
JPH07257419A (ja) 1994-03-24 1995-10-09 Kubota Corp 農作業車
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
WO1996013589A1 (en) * 1994-10-27 1996-05-09 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
GB0210741D0 (en) 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
WO2006075253A2 (en) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
KR20070110901A (ko) * 2005-03-04 2007-11-20 다이나박스 테크놀로지 코퍼레이션 항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
WO2006132607A1 (en) 2005-06-10 2006-12-14 National University Of Singapore Mutant allergen(s)
US20070092532A1 (en) 2005-10-25 2007-04-26 Board Of Trustees Operating Michigan State University Arthritis vaccines and methods
CN100457180C (zh) * 2005-11-09 2009-02-04 浙江我武生物科技有限公司 用于治疗过敏性疾病的药物组合物及其制备方法
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
EP2153841B2 (en) * 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy

Also Published As

Publication number Publication date
HRP20120206T4 (hr) 2016-02-12
US20120108524A1 (en) 2012-05-03
EP2153841A1 (en) 2010-02-17
US8491910B2 (en) 2013-07-23
EP2153841B1 (en) 2011-12-14
CA2734379A1 (en) 2010-02-18
AU2009281013B2 (en) 2015-01-29
SI2153841T1 (sl) 2012-04-30
PL2153841T5 (pl) 2016-09-30
DK2153841T4 (en) 2016-02-15
WO2010018378A8 (en) 2010-10-28
EP2444100A3 (en) 2012-07-25
CN102170897A (zh) 2011-08-31
SI2153841T2 (sl) 2016-02-29
EP2444100A2 (en) 2012-04-25
HRP20120206T1 (en) 2012-03-31
BRPI0917648A2 (pt) 2015-12-01
US20130295123A1 (en) 2013-11-07
ATE536880T1 (de) 2011-12-15
KR20110044787A (ko) 2011-04-29
WO2010018378A2 (en) 2010-02-18
CN102170897B (zh) 2015-02-04
JP5788319B2 (ja) 2015-09-30
WO2010018378A3 (en) 2010-07-22
US20170014505A1 (en) 2017-01-19
JP2012500193A (ja) 2012-01-05
AU2009281013A1 (en) 2010-02-18
EP2433639A3 (en) 2012-06-27
EA201170336A1 (ru) 2011-10-31
ES2378870T5 (es) 2016-02-03
ES2378870T3 (es) 2012-04-18
CN104710512A (zh) 2015-06-17
US9347937B2 (en) 2016-05-24
MX2011001619A (es) 2011-03-25
PT2153841E (pt) 2012-03-21
EP2433639A2 (en) 2012-03-28
EP2153841B2 (en) 2015-11-11
DK2153841T3 (da) 2012-03-26

Similar Documents

Publication Publication Date Title
HRP20120206T1 (en) Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy
Fuchs et al. Natural latex, grass pollen, and weed pollen share IgE epitopes
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
IN2012DN03368A (pl)
WO2004081028A3 (en) Allergen peptide fragments and use thereof
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NZ594268A (en) Grass peptides for vaccine
WO2008098749A3 (en) Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
MX2020012569A (es) Moleculas inmunoterapeuticas novedosas y sus usos.
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
WO2006072946A3 (en) Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
ATE400581T1 (de) Peptid-antioxidantien aus sojaproteinen
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
WO2015131053A1 (en) Polypeptides derived from phl p and methods and uses thereof for immune response modulation
WO2012170842A3 (en) Peptide for protection of allergic respiratory disorders
WO2012073045A3 (en) Variants of trappins
WO2016209959A2 (en) Peptide combinations and use thereof in treating cedar pollen allergy
WO2007048100A3 (en) Angio-inhibitory peptides derived from human timp-2
UA97631C2 (en) Therapeutic vaccine
DE602007009797D1 (de) Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon